OBJECTIVE: To identify and estimate the common effect size of HLA-Class II contributing to susceptibility on T1D in Latin America (LA) through a meta-analysis. METHODS: A systematic review of the literature searching for all HLA-Class II alleles and susceptibility for T1D case-control studies performed in LA was made up to October 2009. Effect summary ORs and 95% CI were obtained by means of the random effect model. A prediction model that identifies peptides binding to HLA-DR alleles that were significantly associated with T1D throughout the meta-analysis was done. RESULTS: 21 studies were included (1138 cases and 1920 controls). DRB1*0301 (OR: 9.65; 95% CI: 5.69-16.36; p<0.0001), DRB1*1201 (OR: 4.84; 95% CI: 1.97-11.91; p=0.001), DQB1*0302 (OR: 4.58; 95% CI: 3.36-6.26; p<0.0001), DQA1*0301(OR: 3.02; 95% CI: 1.37-6.65; p=0.0059) and DQB1*0602 (OR: 0.19; 95% CI: 0.11-0.33; p<0.0001), DRB1*14 (OR: 0.18; 95% CI: 0.06-0.55; p=0.0024), and DQB1*0501 (OR: 0.47; 95% CI: 0.26-0.83; p=0.0097) were the most significant alleles associated with T1D. DRB1*0301-DQA1*0501-DQB1*0201 (OR: 13.50; 95% CI: 3.85-47.28; p<0.0001) and DRB1*1301-DQB1*0603 (OR: 0.25; 95% CI: 0.1-0.65; p=0.004) were the most significant risk and protective haplotypes associated, respectively. There were peptides binding to significantly HLA-DRB1 alleles and haplotypes found through the meta-analysis from islet cell protein tyrosine phosphatase and glutamic acid decarboxylase. CONCLUSIONS: These results strengthen the effect of HLA-Class II on T1D in LA similar to Caucasians regardless of the latitudinal gradient and admixture. The shared chemical characteristics in critical pockets could explain the predisposition to present a "diabetogenic peptide" to T cells in this population. 2010 Elsevier B.V. All rights reserved.
OBJECTIVE: To identify and estimate the common effect size of HLA-Class II contributing to susceptibility on T1D in Latin America (LA) through a meta-analysis. METHODS: A systematic review of the literature searching for all HLA-Class II alleles and susceptibility for T1D case-control studies performed in LA was made up to October 2009. Effect summary ORs and 95% CI were obtained by means of the random effect model. A prediction model that identifies peptides binding to HLA-DR alleles that were significantly associated with T1D throughout the meta-analysis was done. RESULTS: 21 studies were included (1138 cases and 1920 controls). DRB1*0301 (OR: 9.65; 95% CI: 5.69-16.36; p<0.0001), DRB1*1201 (OR: 4.84; 95% CI: 1.97-11.91; p=0.001), DQB1*0302 (OR: 4.58; 95% CI: 3.36-6.26; p<0.0001), DQA1*0301(OR: 3.02; 95% CI: 1.37-6.65; p=0.0059) and DQB1*0602 (OR: 0.19; 95% CI: 0.11-0.33; p<0.0001), DRB1*14 (OR: 0.18; 95% CI: 0.06-0.55; p=0.0024), and DQB1*0501 (OR: 0.47; 95% CI: 0.26-0.83; p=0.0097) were the most significant alleles associated with T1D. DRB1*0301-DQA1*0501-DQB1*0201 (OR: 13.50; 95% CI: 3.85-47.28; p<0.0001) and DRB1*1301-DQB1*0603 (OR: 0.25; 95% CI: 0.1-0.65; p=0.004) were the most significant risk and protective haplotypes associated, respectively. There were peptides binding to significantly HLA-DRB1 alleles and haplotypes found through the meta-analysis from islet cell protein tyrosine phosphatase and glutamic acid decarboxylase. CONCLUSIONS: These results strengthen the effect of HLA-Class II on T1D in LA similar to Caucasians regardless of the latitudinal gradient and admixture. The shared chemical characteristics in critical pockets could explain the predisposition to present a "diabetogenic peptide" to T cells in this population. 2010 Elsevier B.V. All rights reserved.
Authors: H P V Silva; M A G Ururahy; K S C Souza; M B Loureiro; Y M C Oliveira; G H M Oliveira; A D Luchessi; K T C Carvalho; J C O C Freitas; E A Donadi; R D C Hirata; M G Almeida; R F Arrais; M H Hirata; A A Rezende Journal: Genes Immun Date: 2015-10-22 Impact factor: 2.676
Authors: Zemin Zhou; Eduardo Reyes-Vargas; Hernando Escobar; Brant Rudd; Alan L Rockwood; Julio C Delgado; Xiao He; Peter E Jensen Journal: Eur J Immunol Date: 2016-01-22 Impact factor: 5.532
Authors: Juan-Manuel Anaya; Xana Kim-Howard; Sampath Prahalad; Alejandra Cherñavsky; Carlos Cañas; Adriana Rojas-Villarraga; John Bohnsack; Roland Jonsson; Anne Isine Bolstad; Johan G Brun; Beth Cobb; Kathy L Moser; Judith A James; John B Harley; Swapan K Nath Journal: Autoimmun Rev Date: 2011-08-05 Impact factor: 9.754
Authors: Anja Panhuber; Giovanni Lamorte; Veronica Bruno; Hakan Cetin; Wolfgang Bauer; Romana Höftberger; Astrid C Erber; Florian Frommlet; Inga Koneczny Journal: Sci Rep Date: 2022-06-02 Impact factor: 4.996
Authors: Youssef M Mosaad; Fatma A Auf; Shereen S Metwally; Ashraf A Elsharkawy; Amany K El-Hawary; Rasha H Hassan; Ziyad E Tawhid; Farha A El-Chennawi Journal: World J Diabetes Date: 2012-08-15
Authors: Sigrid Naess; Einar Björnsson; Jarl A Anmarkrud; Said Al Mamari; Brian D Juran; Konstantinos N Lazaridis; Roger Chapman; Annika Bergquist; Espen Melum; Steven G E Marsh; Erik Schrumpf; Benedicte A Lie; Kirsten M Boberg; Tom H Karlsen; Johannes R Hov Journal: Liver Int Date: 2014-03-07 Impact factor: 5.828